Lumicell
Newton, MA · Biotechnology · 63 employees
Lumicell is a privately held company focused on innovative fluorescence-guided technologies for cancer surgery with the potential to improve patient outcomes and reduce healthcare costs. The company’s first product is the Lumicell Direct Visualization System, designed to provide real-time illumination of cancerous tissue within the breast cavity during the initial lumpectomy, potentially reducing
Funding history
- Funding Round — $198.1M — May 2025
- Funding Round — $2.7M — Jul 2024
- Series seed — $2.3M — Mar 2024
- Funding Round — $75.8M — Jul 2023
- Funding Round — $20.4M — Dec 2018
Recent signals
- May 28, 2026: Lumicell Promotes Marnie Curbow to Chief Commercial Officer
- May 06, 2025: Raised $198.1M
- Nov 13, 2024: Lumicell Appoints Howard Hechler as Chief Executive Officer
- Sep 30, 2024: Lumicell Awarded Phase I NIH SBIR Contract to Develop Novel Flexible Endoscope for Fluorescence Imaging of LUMISIGHT™ to Detect Early Esophageal Lesions
- Jul 25, 2024: Raised $2.7M
- Mar 08, 2024: Raised $2.3M in Series seed
- Jul 26, 2023: Raised $75.8M
- Dec 20, 2018: Raised $20.4M
See plans & pricing → Track Lumicell’s funding, hiring, and signals — with verified contacts — on Fundz.